lansoprazole has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishi, T | 1 |
| Yamamoto, Y | 1 |
| Yamagishi, N | 1 |
| Iguchi, M | 1 |
| Tamai, H | 1 |
| Ito, T | 1 |
| Tsuruo, Y | 1 |
| Ichinose, M | 1 |
| Kitano, M | 1 |
| Ueyama, T | 1 |
1 other study available for lansoprazole and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
Topics: Animals; Aspartate Aminotransferases; Diet; Disease Models, Animal; Disease Progression; Heme Oxygen | 2018 |